Immunome, Inc. $IMNM Shares Acquired by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. grew its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 55.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 775,000 shares of the company's stock after acquiring an additional 275,000 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 0.89% of Immunome worth $5,216,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in shares of Immunome in the fourth quarter worth $70,000. ANTIPODES PARTNERS Ltd acquired a new stake in Immunome in the 1st quarter valued at approximately $95,000. KLP Kapitalforvaltning AS grew its holdings in shares of Immunome by 140.8% during the 1st quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock worth $115,000 after purchasing an additional 10,000 shares in the last quarter. Teacher Retirement System of Texas raised its position in Immunome by 49.0% in the 1st quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company's stock valued at $117,000 after purchasing an additional 5,712 shares during the last quarter. Finally, Arizona State Retirement System raised its position in shares of Immunome by 66.2% during the first quarter. Arizona State Retirement System now owns 18,764 shares of the company's stock worth $126,000 after acquiring an additional 7,476 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Price Performance

NASDAQ IMNM traded up $0.53 during trading hours on Friday, reaching $10.21. The company's stock had a trading volume of 347,534 shares, compared to its average volume of 990,650. The company's 50-day moving average is $9.93 and its two-hundred day moving average is $8.84. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $16.73. The firm has a market capitalization of $888.68 million, a price-to-earnings ratio of -3.28 and a beta of 1.92.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. The business had revenue of $4.02 million during the quarter, compared to analyst estimates of $1.03 million. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. Equities analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IMNM. JPMorgan Chase & Co. lowered their price target on Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Wall Street Zen raised Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Evercore ISI initiated coverage on Immunome in a report on Friday, August 22nd. They issued an "outperform" rating and a $18.00 target price for the company. Guggenheim reiterated a "buy" rating and issued a $25.00 price target on shares of Immunome in a research report on Monday, August 25th. Finally, Wedbush reaffirmed an "outperform" rating and set a $21.00 price target on shares of Immunome in a research report on Thursday, August 7th. Nine investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $22.89.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.